G Mancia


Affiliation: University of Milano-Bicocca
Country: Italy


  1. Mancia G, Grassi G. The central sympathetic nervous system in hypertension. Handb Clin Neurol. 2013;117:329-35 pubmed publisher
    ..The above mentioned sympathetic abnormalities explain why adrenergic overdrive represents an important therapeutic target in the treatment of hypertension. ..
  2. Mancia G, Grassi G. Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach. Diabetologia. 2018;61:517-525 pubmed publisher
    ..However, evidence in favour of even lower systolic values, i.e. <130 mmHg, is limited and is definitively against a reduction to <120 mmHg. ..
  3. Mancia G, Facchetti R, Parati G, Zanchetti A. Effect of long-term antihypertensive treatment on white-coat hypertension. Hypertension. 2014;64:1388-98 pubmed publisher
    ..The consequence of this contrasting effect on the incidence of hypertension-related outcomes remains to be established. ..
  4. Bombelli M, Facchetti R, Cuspidi C, Villa P, Dozio D, Brambilla G, et al. Prognostic significance of left atrial enlargement in a general population: results of the PAMELA study. Hypertension. 2014;64:1205-11 pubmed publisher
    ..Thus, like LVH, LA enlargement is an independent long-term predictor of cardiovascular events. The cardiovascular risk, however, is not further increased when LA enlargement is superimposed on an increase of LV mass. ..
  5. Bombelli M, Fodri D, Toso E, Macchiarulo M, Cairo M, Facchetti R, et al. Relationship among morning blood pressure surge, 24-hour blood pressure variability, and cardiovascular outcomes in a white population. Hypertension. 2014;64:943-50 pubmed publisher
  6. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti Trevano F, Polo Friz H, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226-32 pubmed publisher
    ..Subjects with WCHT and MHT are at increased risk of developing SHT. This may contribute to their prognosis that appears to be worse as compared with that of normotensive subjects. ..
  7. Mancia G. Defining blood pressure goals: is it enough to manage total cardiovascular risk?. J Hypertens Suppl. 2009;27:S3-8 pubmed publisher
    ..A further consideration in managing total cardiovascular risk is the need for multiple antihypertensive agents to control BP. ..
  8. Mancia G, Laurent S, Agabiti Rosei E, Ambrosioni E, Burnier M, Caulfield M, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-58 pubmed publisher
  9. Mancia G, Laurent S, Agabiti Rosei E, Ambrosioni E, Burnier M, Caulfield M, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18:308-47 pubmed publisher

More Information


  1. request reprint
    Mancia G. Prevention and treatment of stroke in patients with hypertension. Clin Ther. 2004;26:631-48 pubmed
  2. Mancia G, Kjeldsen S, Zappe D, Holzhauer B, Hua T, Zanchetti A, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J. 2016;37:955-64 pubmed publisher
    ..Thus, aggressive BP reductions when CV risk is high may not offer substantial advantages, except perhaps in patients or conditions in which stroke risk is particularly common. ..
  3. Mancia G, Parati G, Revera M, Bilo G, Giuliano A, Veglia F, et al. Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. BMJ. 2010;340:c1197 pubmed publisher
    ..Trial registration BRISQUI_*IV_2004_001 (registered at Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali-National Monitoring Centre on Clinical Research with Medicines). ..
  4. Mancia G. Effects of intensive blood pressure control in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010;122:847-9 pubmed publisher
  5. Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. Circ Res. 2015;116:1034-45 pubmed publisher
  6. Mancia G, Bombelli M, Brambilla G, Facchetti R, Sega R, Toso E, et al. Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension. 2013;62:168-74 pubmed publisher
    ..89; P<0.0001). Thus, WCH includes subjects with a widely different long-term risk of a cardiovascular event. To identify those at higher risk, measurements of both out-of-office BPs are desirable. ..
  7. Mancia G, Facchetti R, Grassi G, Bombelli M. Adverse prognostic value of persistent office blood pressure elevation in white coat hypertension. Hypertension. 2015;66:437-44 pubmed publisher
    ..This means that in WCH office BP is prognostically relevant and that repeated collection of its values is clinically important to better define patient risk. ..
  8. Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124:1727-36 pubmed publisher
    ..Overall, CV protection was favorably affected by the less tight but not by the tighter BP target. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00153101. ..
  9. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti Trevano F, Grassi G, et al. Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens. 2009;27:1672-8 pubmed publisher
    ..This is largely accounted for by the metabolic abnormalities that are frequent components of these conditions. ..
  10. Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano F, et al. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens. 2008;26:1602-11 pubmed publisher
    ..This may account for the increased rate of cardiovascular morbidity and mortality exhibited with this condition in long-term studies. ..
  11. Mancia G, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219 pubmed publisher
  12. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. Circulation. 2012;126:569-78 pubmed publisher
    ..Thus, when BP is modestly elevated, inconsistency of BP control between visits plays a less important prognostic role than long-term average BP levels. ..
  13. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens. 2012;30:1241-51 pubmed publisher
    ..Interindividual BP variability during treatment shows marked quantitative differences with intraindividual BP variability questioning whether its use can accurately reflect individual BP variations from one visit to another. ..
  14. request reprint
    Mancia G, Cannon C, Tikkanen I, Zeller C, Ley L, Woerle H, et al. Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication. Hypertension. 2016;68:1355-1364 pubmed
    ..URL: https://clinicaltrials.gov. Unique identifier: NCT01370005. ..
  15. Mancia G, Rosei E, Ambrosioni E, Avino F, Carolei A, Daccò M, et al. Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: evidence from a large, multicenter, cross-sectional survey in Italy (MIRACLES study). J Hypertens. 2011;29:309-18 pubmed publisher
  16. Morganti A, Mancia G. Resistant hypertension: Renal denervation or intensified medical treatment?. Eur J Intern Med. 2018;50:6-11 pubmed publisher
    ..At present, it is advisable to treat RH with the addition of an anti-aldosterone agent. If BP control is not achieved or serious side effects become manifest RDN may then be considered. ..
  17. Mancia G, Schumacher H, Bohm M, Redon J, Schmieder R, Verdecchia P, et al. Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. Hypertension. 2017;70:938-948 pubmed publisher
    ..Prediction improved by their combined use, which may thus offer a more precise estimate of the protective effect of treatment. URL: http//www.clinicaltrial.gov. Unique identifier: NCT153.101. ..